amifostine anhydrous has been researched along with Emesis in 18 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty women with metastatic breast cancer were randomized to receive either paclitaxel alone (arm 1) or paclitaxel preceded by amifostine (arm 2)." | 9.09 | Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. ( Batist, G; Blackstein, M; Bryce, C; Eisenhauer, E; Fisher, B; Gelmon, K; Iglesias, J; Mayer, L; Tolcher, A; Tomiak, E; Tomlinson, E; Yau, J; Zee, B, 1999) |
| "Forty women with metastatic breast cancer were randomized to receive either paclitaxel alone (arm 1) or paclitaxel preceded by amifostine (arm 2)." | 5.09 | Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. ( Batist, G; Blackstein, M; Bryce, C; Eisenhauer, E; Fisher, B; Gelmon, K; Iglesias, J; Mayer, L; Tolcher, A; Tomiak, E; Tomlinson, E; Yau, J; Zee, B, 1999) |
| "High-dose melphalan (HDM) followed by autologous hematopoietic cell transplantation (auto-HCT) remains the standard-of-care therapy for multiple myeloma (MM) even with the availability of proteasome inhibitors and immunomodulatory drugs." | 3.88 | Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. ( Bashir, Q; Caimi, P; Champlin, R; Cooper, B; Covut, F; Creger, R; de Lima, M; Delgado, R; Gupta, V; Lazarus, HM; Malek, E; Qazilbash, M; Rondon, G; Vatsayan, A, 2018) |
| " We evaluated the toxicity and efficacy of a Hypofractionated and intensively Accelerated RT regimen supported with amifostine Cytoprotection (HypoARC) in a cohort of 72 high-risk breast cancer patients treated with modified mastectomy or conservative surgery and FEC (5-fluorouracil/epirubicin/cyclophosphamide) chemotherapy." | 3.71 | Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. ( Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E, 2002) |
| " This is the first report focusing on amifostine related adverse effects leading to discontinuation of amifostine treatment." | 2.71 | Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. ( Alberti, W; Bajrovic, A; Fehlauer, F; Mahlmann, B; Rades, D; Richter, E, 2004) |
| " We conducted a clinical and pharmacokinetic pilot study to assess the feasibility and toxicity of the docetaxel plus amifostine combination and the absence of influence of amifostine on docetaxel pharmacokinetics." | 2.70 | Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. ( Awada, A; Brassinne, C; de Valeriola, D; Freyer, G; Gil, T; Hennebert, P; Kerger, J; Piccart, M; Selleslags, J, 2002) |
| "Emesis was significantly influenced by infusion time; the long schedule caused a 57% incidence whereas the short schedule caused only a 28% incidence." | 1.27 | Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]. ( Glick, J; Glover, DJ; Hurwitz, S; Kligerman, MM; Norfleet, AL; Turrisi, AT; Weiler, C; Yuhas, JM, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (16.67) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 10 (55.56) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malek, E | 1 |
| Gupta, V | 1 |
| Creger, R | 1 |
| Caimi, P | 1 |
| Vatsayan, A | 1 |
| Covut, F | 1 |
| Bashir, Q | 1 |
| Champlin, R | 1 |
| Delgado, R | 1 |
| Rondon, G | 1 |
| Cooper, B | 1 |
| de Lima, M | 1 |
| Lazarus, HM | 1 |
| Qazilbash, M | 1 |
| Soref, CM | 1 |
| Hacker, TA | 1 |
| Fahl, WE | 1 |
| Koukourakis, MI | 2 |
| Simopoulos, C | 1 |
| Minopoulos, G | 1 |
| Patlakas, G | 1 |
| Polychronidis, A | 1 |
| Limberis, V | 1 |
| Romanides, K | 1 |
| Pitiacoudis, M | 1 |
| Manolas, C | 1 |
| Rades, D | 1 |
| Fehlauer, F | 1 |
| Bajrovic, A | 1 |
| Mahlmann, B | 1 |
| Richter, E | 1 |
| Alberti, W | 1 |
| Anné, PR | 1 |
| Machtay, M | 1 |
| Rosenthal, DI | 1 |
| Brizel, DM | 1 |
| Morrison, WH | 1 |
| Irwin, DH | 1 |
| Chougule, PB | 1 |
| Estopinal, NC | 1 |
| Berson, A | 1 |
| Curran, WJ | 1 |
| Gallegos-Castorena, S | 1 |
| Martínez-Avalos, A | 1 |
| Mohar-Betancourt, A | 1 |
| Guerrero-Avendaño, G | 1 |
| Zapata-Tarrés, M | 1 |
| Medina-Sansón, A | 1 |
| Cairnie, AB | 1 |
| Ramnath, N | 1 |
| LoRusso, P | 1 |
| Simon, M | 1 |
| Martino, S | 1 |
| Gelmon, K | 1 |
| Eisenhauer, E | 1 |
| Bryce, C | 1 |
| Tolcher, A | 1 |
| Mayer, L | 1 |
| Tomlinson, E | 1 |
| Zee, B | 1 |
| Blackstein, M | 1 |
| Tomiak, E | 1 |
| Yau, J | 1 |
| Batist, G | 1 |
| Fisher, B | 1 |
| Iglesias, J | 1 |
| Chauncey, TR | 1 |
| Gooley, TA | 1 |
| Lloid, ME | 1 |
| Schubert, MM | 1 |
| Lilleby, K | 1 |
| Holmberg, L | 1 |
| Bensinger, WI | 1 |
| Capelli, D | 1 |
| Santini, G | 1 |
| De Souza, C | 1 |
| Poloni, A | 1 |
| Marino, G | 1 |
| Montanari, M | 1 |
| Lucesole, M | 1 |
| Brunori, M | 1 |
| Massidda, D | 1 |
| Offidani, M | 1 |
| Leoni, P | 1 |
| Olivieri, A | 1 |
| Fulda, S | 1 |
| Fichtner, I | 1 |
| Hero, B | 1 |
| Berthold, F | 1 |
| Yavuz, AA | 1 |
| Aydin, F | 1 |
| Yavuz, MN | 1 |
| Ilis, E | 1 |
| Ozdemir, F | 1 |
| Giatromanolaki, A | 1 |
| Kouroussis, C | 1 |
| Kakolyris, S | 1 |
| Sivridis, E | 1 |
| Frangiadaki, C | 1 |
| Retalis, G | 1 |
| Georgoulias, V | 1 |
| Freyer, G | 1 |
| Hennebert, P | 1 |
| Awada, A | 1 |
| Gil, T | 1 |
| Kerger, J | 1 |
| Selleslags, J | 1 |
| Brassinne, C | 1 |
| Piccart, M | 1 |
| de Valeriola, D | 1 |
| Gralla, EJ | 1 |
| Sabo, JP | 1 |
| Hayden, DW | 1 |
| Yochmowitz, MG | 1 |
| Mattsson, JL | 1 |
| Buzaid, AC | 1 |
| Murren, J | 1 |
| Durivage, HJ | 1 |
| Turrisi, AT | 1 |
| Glover, DJ | 1 |
| Hurwitz, S | 1 |
| Glick, J | 1 |
| Norfleet, AL | 1 |
| Weiler, C | 1 |
| Yuhas, JM | 1 |
| Kligerman, MM | 1 |
10 trials available for amifostine anhydrous and Emesis
| Article | Year |
|---|---|
Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Inciden | 2007 |
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
Topics: Adolescent; Amifostine; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2007 |
Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone | 1997 |
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Combined Mod | 1999 |
Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study.
Topics: Adolescent; Adult; Aged; Amifostine; Analgesics, Opioid; Antineoplastic Agents, Alkylating; Blood Ce | 2000 |
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Divi | 2001 |
Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Pro | 2001 |
Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Therap | 2002 |
High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Drug | 1991 |
8 other studies available for amifostine anhydrous and Emesis
| Article | Year |
|---|---|
Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.
Topics: Adult; Aged; Amifostine; Case-Control Studies; Combined Modality Therapy; Diarrhea; Disease-Free Sur | 2018 |
A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses.
Topics: Administration, Oral; Amifostine; Animals; Diamines; Drug Evaluation, Preclinical; Female; Ferrets; | 2012 |
Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Routes; | 2003 |
Adverse effects of radioprotector WR2721.
Topics: Amifostine; Animals; Conditioning, Psychological; Diet; Dose-Response Relationship, Drug; Male; Naus | 1983 |
Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Topics: Adult; Aged; Amifostine; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2000 |
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breas | 2002 |
The effect of selected drugs on first-stage radioemesis in beagle dogs.
Topics: Amifostine; Amphetamine; Animals; Antiemetics; Body Weight; Chlorpromazine; Dimenhydrinate; Diphenhy | 1979 |
Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid].
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Drug Evaluation; Female; Humans; Hypotension; Infusi | 1986 |